Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification.

T-cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50-60% of the T-cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second-generation tyrosine kinase inhibitor, directly targets the BCR-ABL gene. We describe a pediatric case of T-cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy.
AuthorsOfelia Crombet, Kelly Lastrapes, Arthur Zieske, Jaime Morales-Arias
JournalPediatric blood & cancer (Pediatr Blood Cancer) Vol. 59 Issue 2 Pg. 333-4 (Aug 2012) ISSN: 1545-5017 [Electronic] United States
PMID22689211 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2011 Wiley Periodicals, Inc.
Chemical References
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Proto-Oncogene Proteins c-abl
  • Dasatinib
  • Child
  • Dasatinib
  • Female
  • Gene Amplification
  • Humans
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, genetics, pathology)
  • Protein Kinase Inhibitors (therapeutic use)
  • Proto-Oncogene Proteins c-abl (genetics)
  • Pyrimidines (therapeutic use)
  • Remission Induction
  • Thiazoles (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: